

## ONWARD Announces Results of Annual General Meeting of Shareholders

*Shareholders approve all proposed resolutions*

EINDHOVEN, the Netherlands — May 8, 2023 — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies for people with spinal cord injury, today announces all proposed resolutions at its Annual General Meeting of Shareholders (AGM) were duly passed. The meeting was held this afternoon in Amsterdam, the Netherlands at 2.00 p.m. CET. Full details of the resolutions approved during the AGM can be found on [IR.ONWD.com](https://ir.onwd.com).

To learn more about ONWARD ARC Therapy™ and the Company's vision to restore movement, function, and independence in people with spinal cord injury, please visit [ONWD.com](https://onwd.com).

### About ONWARD® Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. The Company's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD ARC Therapy™, which can be delivered by implantable (ARC-IM™) or external (ARC-EX™) systems\*, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received eight Breakthrough Device Designations from the US FDA. ARC-EX is an external, non-invasive platform consisting of a stimulator and wireless programmer. Positive top-line data were reported in 2022 from the Company's first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The Company is now preparing marketing approval submissions for the US and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed the first-in-human use of the ARC-IM neurostimulator and reported positive interim clinical outcomes for ARC-IM Therapy for improved blood pressure regulation following SCI in 2022.

ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between EPFL, the Swiss Federal Institute of Technology in Lausanne, and Lausanne University Hospital (CHUV). For additional information about the Company, please visit [ONWD.com](https://onwd.com). To access our 2023 Financial Calendar, please visit [IR.ONWD.com](https://ir.onwd.com).

\*Devices are for investigational use only

**For Company Enquiries:**

[info@onwd.com](mailto:info@onwd.com)

**For Media Enquiries:**

Aditi Roy, VP Communications

[media@onwd.com](mailto:media@onwd.com)

**For Investor Enquiries:**

Lara Smith Weber, CFO

[investors@onwd.com](mailto:investors@onwd.com)

**Disclaimer**

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.